Latest Breaking News On - Calistoga pharmaceuticals inc - Page 1 : comparemela.com

Published: May 05, 2021     BERKELEY, Calif. (BUSINESS WIRE) Caribou Biosciences, Inc,   a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Andrew Guggenhime to its board of directors. Mr. Guggenhime is an accomplished biopharmaceutical industry leader with more than 20 years of experience. “Andrew brings a wealth of financial, strategic, and operational leadership experience in both private and public healthcare company settings,” said Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer. “We are delighted to welcome him to our board of directors and look forward to benefitting from his expertise as we continue to build the company and advance our pipeline of chRDNA-edited allogeneic cell therapies.”

United statesRachel haurwitzAndrew guggenhimeEli lillyFacet biotech corporationMiddlebury collegeGilead sciences incCalistoga pharmaceuticals incCaribou biosciences incWells fargo companyDermira incInternational politicsMerrill lynch coVaxcyte incAbbott laboratoriesMetacrine inc